RecruitingNCT06430983

Recurrent Liver Cancer: Reconceptualization and Reevaluation


Sponsor

Nanjing Medical University

Enrollment

300 participants

Start Date

Jul 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer. The study will focus on recurrent liver cancer patients and compare participants to primary liver cancer patients as controls. The primary purpose is to assess whether the elevated levels of this protein can be used to monitor the recurrence of liver cancer. The main questions it aims to answer are: Is the levels of the protein significantly elevated in recurrent liver cancer patients compared to primary liver cancer patients? Can the protein be used as a reliable biomarker for the early detection of liver cancer recurrence? Researchers will compare the protein levels in the following groups: 50 recurrent liver cancer patients (training set) with abnormally high levels of the protein. 250 recurrent liver cancer patients (validation set) to confirm the protein's elevation in a separate cohort. Participants will be required to: * Provide blood samples for protein analysis. * Undergo regular follow-up visits for monitoring and data collection. * Allow access to their medical records for relevant clinical information.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at patients with liver cancer — both primary liver cancer (hepatocellular carcinoma) and cancers that have spread to the liver from elsewhere — to better understand when and how liver cancer comes back after treatment. **You may be eligible if...** - You have been diagnosed with primary liver cancer (hepatocellular carcinoma) or cancer that spread to the liver from another organ - You are willing to provide a blood sample - You can provide basic identifying information and have documentation of your diagnosis - You or your legal representative can read and sign the informed consent form **You may NOT be eligible if...** - You are pregnant - You have received an organ transplant - You have a non-liver cancer that has spread to the liver AND also have another separate cancer diagnosis - You have primary liver cancer that also has signs of spreading (vascular invasion or spread outside the liver) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06430983


Related Trials